At ASH Celgene's (CELG) Revlimid Remains Preferred Backbone - BMO
Tweet Send to a Friend
BMO Capital analyst M. Ian Somaiya reiterated an Outperform rating and $142 price target on Celgene (NASDAQ: CELG) noting at ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
